News of Note—Merck’s Zostavax, GeoVax and more

In this week's news of note, an appeals court upheld a lower court's decision to throw out a Zostavax injury lawsuit. (Pixabay)

Here is some other vaccine news of note for the week.

> A U.S. Circuit Court of Appeals affirmed a lower court's decision to throw out a Zostavax injury lawsuit against Merck due to the statute of limitations. Court opinion (PDF)

> GeoVax nabbed $300,000 from the NIH’s National Institute of Allergy and Infectious Diseases to support a phase 1 study of its Lassa fever vaccine program. Release

> The University of Washington’s Institute for Protein Design won a $11.3 million grant from the Open Philanthropy Project; about half of it will go toward the development of a universal flu vaccine. GeekWire article

> Using education campaigns to change people’s minds about vaccines is less effective than using behavioral nudges, a new study published in Psychological Science in the Public Interest found. Release

Suggested Articles

GSK expects Shingrix supplies to rise slightly in 2020, but the real "step change" will come in 2024 with a brand-new manufacturing facility.

Ebola has claimed thousands of lives in recent outbreaks, but now the world has a licensed vaccine option in Merck's Ervebo.

Cosette Pharmaceuticals which was formed in December with a deal for dermatology projects has gone back to G&W Labs for a liquids plant.